Encompass Health Reports Strong 2025 Financials with Double-Digit Revenue and EPS Growth, Increases Dividend
Summary
Encompass Health Corp reported strong 2025 financial results with double-digit growth in revenue, net income, and EPS, alongside increased dividends and share repurchases, while detailing its growth strategy and regulatory environment.
Key Events
-
Strong Financial Performance in 2025
Net operating revenues increased by 10.5% to $5.94 billion, net income attributable to Encompass Health rose 24.2% to $566.2 million, and diluted earnings per share (EPS) reached $5.54. Cash flow from operating activities also grew by 17.2% to $1.18 billion.
-
Increased Shareholder Returns
The company increased its quarterly cash dividend to $0.19 per share in July 2025 and repurchased 1.5 million shares of common stock for $158.0 million in 2025, with approximately $332 million remaining under the current authorization.
-
Continued Strategic Growth
Encompass Health expanded its network by opening 7 new inpatient rehabilitation hospitals and adding 177 beds to existing facilities in 2025, with further development plans outlined for 2026 and 2027.
-
Regulatory and Operational Updates
The 2026 IRF Rule is expected to result in a net 2.9% increase in Medicare payment rates for the company. The Review Choice Demonstration (RCD) program expanded to Texas and California, impacting 33 hospitals (11.9% of IRF Medicare claims), with the company noting inconsistent review processes by MACs.
Analysis
Encompass Health Corp's 2025 annual report reveals robust financial performance, with net operating revenues increasing by 10.5% to $5.94 billion and net income attributable to the company rising 24.2% to $566.2 million, translating to diluted EPS of $5.54. Cash flow from operations also saw a significant 17.2% increase to $1.18 billion. The company continued its growth strategy by opening 7 new inpatient rehabilitation hospitals and adding 177 beds to existing facilities in 2025, with further expansion planned for 2026-2027. Shareholder returns were enhanced through $158.0 million in common stock repurchases and an increased quarterly dividend of $0.19 per share. While the regulatory landscape remains complex, with a 2.9% net increase in Medicare payment rates for FY2026 and the expansion of the Review Choice Demonstration (RCD) to key states, the company has provided extensive details on its cybersecurity risk management, noting no material compromises to date. This comprehensive annual report confirms the strong financial health and strategic direction of the company, building on the preliminary results announced earlier this month.
At the time of this filing, EHC was trading at $107.92 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.9B. The 52-week trading range was $92.53 to $127.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.